New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments
A new briefing paper based on Medicines Law & Policy research outlines the legal instruments available for countries seeking to access key therapeutics to...
Wrapping up 2020 with some noteworthy medicines, law and policy events
Wrapping up the year 2020 can’t happen soon enough. This year, one way or the other, most people on the planet have been affected...
Wrapping up 2023 with some noteworthy medicines, law and policy developments
Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...
Time for new pharmaceutical-innovation models
The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year,...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
Uganda tells ARIPO: No more patents for pharmaceuticals
Uganda has notified the African Regional Intellectual Property Organisation (ARIPO) that pharmaceutical inventions are not eligible for patentability in the country, Managing IP reported.
With...
Generic versions of a lifesaving cystic fibrosis treatment will save patients $360,000 a year...
Generic versions of a cystic fibrosis treatment will now be available at $6,375 per child, per year under a new scheme – offering hope...
The People vs. AbbVie
Today, 9 May 2025, is an important day in court for the Dutch Pharmaceutical Accountability Foundation (PAF). In February 2023, PAF started a court...
Wrapping Up 2017 – some noteworthy medicines law and policy events.
2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...
Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...
On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...